share_log

6-K: Financial Report for the Period 1 January 2024 to 30 June 2024

6-K: Financial Report for the Period 1 January 2024 to 30 June 2024

6-K: 2024年1月1日至2024年6月30日期間的財務報告
美股sec公告 ·  08/07 06:56
Moomoo AI 已提取核心訊息
Novo Nordisk A/S, a global healthcare leader in diabetes care, reported a significant increase in sales and operating profit for the first half of 2024. Sales rose by 24% in Danish kroner and 25% at constant exchange rates (CER) to DKK 133.4 billion, while operating profit grew by 18% in Danish kroner and 19% at CER to DKK 57.8 billion. The company's performance was particularly strong in North America, with a 36% increase in sales. Diabetes and Obesity care sales surged by 26% in Danish kroner, driven by GLP-1 diabetes sales growth and Obesity care growing by 37% in Danish kroner. However, rare disease sales saw a decrease. Novo Nordisk also completed the phase 3 FRONTIER 2 trial with Mim8 for haemophilia A and received a positive CHMP opinion for Wegovy in the EU. The company updated its 2024 outlook, expecting sales growth of 22-28% at CER and operating profit growth of 20-28% at CER. The financial report was released on August 7, 2024, alongside an earnings call for investors.
Novo Nordisk A/S, a global healthcare leader in diabetes care, reported a significant increase in sales and operating profit for the first half of 2024. Sales rose by 24% in Danish kroner and 25% at constant exchange rates (CER) to DKK 133.4 billion, while operating profit grew by 18% in Danish kroner and 19% at CER to DKK 57.8 billion. The company's performance was particularly strong in North America, with a 36% increase in sales. Diabetes and Obesity care sales surged by 26% in Danish kroner, driven by GLP-1 diabetes sales growth and Obesity care growing by 37% in Danish kroner. However, rare disease sales saw a decrease. Novo Nordisk also completed the phase 3 FRONTIER 2 trial with Mim8 for haemophilia A and received a positive CHMP opinion for Wegovy in the EU. The company updated its 2024 outlook, expecting sales growth of 22-28% at CER and operating profit growth of 20-28% at CER. The financial report was released on August 7, 2024, alongside an earnings call for investors.
全球醫療保健領導者諾和諾德報告稱，2024年上半年銷售額和營業利潤顯着增長。銷售額在丹麥克朗上漲24％，在恒定匯率下上漲25％（CER）至1334億丹麥克朗，而營業利潤在丹麥克朗上增長18％，在恒定匯率下上漲19％（CER）至578億丹麥克朗。該公司在北美市場表現尤爲強勁，銷售額增長了36％。2型糖尿病和肥胖症護理銷售額在丹麥克朗上激增26％，其中GLP-1糖尿病銷售增長和肥胖症護理銷售增長37％。然而，罕見病的銷售出現了下降。諾和諾德還完成了Mim8用於血友病A的第3期FRONTIER 2試驗，並獲得了Wegovy在歐盟的積極CHMP意見。該公司更新了2024年的前景，預計在CER下銷售增長爲22-28％，營業利潤增長爲20-28％。2024年8月7日，公司發佈了財務報告，並舉行了業績會。
全球醫療保健領導者諾和諾德報告稱，2024年上半年銷售額和營業利潤顯着增長。銷售額在丹麥克朗上漲24％，在恒定匯率下上漲25％（CER）至1334億丹麥克朗，而營業利潤在丹麥克朗上增長18％，在恒定匯率下上漲19％（CER）至578億丹麥克朗。該公司在北美市場表現尤爲強勁，銷售額增長了36％。2型糖尿病和肥胖症護理銷售額在丹麥克朗上激增26％，其中GLP-1糖尿病銷售增長和肥胖症護理銷售增長37％。然而，罕見病的銷售出現了下降。諾和諾德還完成了Mim8用於血友病A的第3期FRONTIER 2試驗，並獲得了Wegovy在歐盟的積極CHMP意見。該公司更新了2024年的前景，預計在CER下銷售增長爲22-28％，營業利潤增長爲20-28％。2024年8月7日，公司發佈了財務報告，並舉行了業績會。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息